Meeting
2021 ASCO Annual Meeting
Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Early results from a multicenter phase I trial.
Authors
Shearwood McClelland III
Indiana University School of Medicine, Indianapolis, IN
Shearwood McClelland III, Tim Lautenschlaeger , Kevin Shiue , Amy C. Miller , Yong Zang , Kathryn I Lauer , Nasser H. Hanna , Ryan Rhome , Namita Agrawal , Paul Anthony , Mu Shan , Jerry Jeff Jaboin , Gordon A Watson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Clinical Trial Registration Number
NCT04047602
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2025)
DOI
10.1200/JCO.2021.39.15_suppl.2025
Abstract #
2025
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Results of an a priori interim analysis of a multicenter phase I trial.
First Author: Shearwood McClelland III
Poster
2022 ASCO Quality Care Symposium
The Inpatient Immunotherapy Outcomes study: A multicenter retrospective study of patients treated with immune checkpoint inhibitors in the inpatient setting.
First Author: Fauzia Riaz
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams
Poster
2022 ASCO Annual Meeting
A retrospective study of ipilimumab plus nivolumab in anti–PD-L1/PD-1-refractory merkel cell carcinoma.
First Author: Sophia Z. Shalhout